E!11284, P-CALPRO, GeticaAB
| Diarienummer | |
| Koordinator | GETICA AB - Sahlgrenska Science Park |
| Bidrag från Vinnova | 3 384 248 kronor |
| Projektets löptid | september 2017 - mars 2020 |
| Status | Avslutat |
| Utlysning | Eurostars – för forskande små och medelstora företag |
Viktiga resultat som projektet gav
The Calprotectin assay has been has been designed, verified and validated in peer reviewed journals and has demonstrated the method and the reagent to be superior to procalcitonin, C-reactive protein in intensive care patients.
Långsiktiga effekter som förväntas
Objectives: To assess the value of plasma calprotectin as an early marker of bacterial infections in critically ill patients and compare it with the corresponding values for procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).
Upplägg och genomförande
Planning the clinical studies was performed and kinetics of calprotectin was investigated in several studies and compared to kinetics of the established biomarkers. When neutrophils were exposed to either E. coli or endotoxin, calprotectin levels began to increase within a couple of hours after the challenge. Calprotectin peaked earlier than comparator soluble mediators (procalcitonin 8hrs, CRP, 24hrs) and exhibited 100% sensitivity. Given the logistic advantages with rapid turbidimetric assay, this is of interest in early diagnosis of bacterial infections.